In a separate study, researchers studying the use of Oncotype DX in African-American men found it to be predictive of disease outcomes regardless of race.

Nvidia customers in the US and the Middle East expect that the newly introduced A100 servers will accelerate research into the novel coronavirus.

Irvine, California-based Fluxergy is working with the MGB Center for COVID Innovation to evaluate the firm's research-use-only COVID-19 testing platform.

RenalytixAI's flagship product is KidneyIntelX, which applies artificial intelligence to patient data to aid in the treatment of progressive kidney disease.

According to the News and Observer, a project aims to analyze the DNA of wild horses from North Carolina's Outer Banks.

According to Nature News, the updated NIH sexual harassment policy does not address all of critics' concerns.

Inside Higher Ed reports faculty members want a say in re-opening discussions.

In PNAS this week: effect of premature termination codons in the DMD gene, knock-down of DUX4 in facioscapulohumeral muscular dystrophy, and more.

Cowen said that Hologic is on track to more than double its Panther system placements to about 500 this year, driven by SARS-CoV-2 test demand.

The platform combines Leica's laser microdissection tool and PBI's pressure cycling tech to enable better extraction and digestion of proteins from biopsies.

Twist Bioscience has launched the Twist Respiratory Virus Research Panel, a next-generation sequencing approach to detecting 29 common human respiratory viruses including SARS-CoV-2, several other coronaviruses, influenzas, rhinoviruses, and respiratory syncytial virus. The research-use-only panel will be bundled with an analysis platform from One Codex to enable a complete workflow beginning with Twist's target enrichment panel and ending with publication-ready visuals, the company said. The panel includes RNA- and DNA-based viruses in one kit with 41,047 nucleic acid probes, can detect as little as 100 copies of viral material, and has coverage of greater than 99.9 percent of the genome at 1X or greater post-enrichment.

The firm said in an SEC document that it received an FDA warning letter in connection with the agency's requirements for its Verigene SP instrument.

Lexent's technology integrates low-pass whole-genome sequencing, fragmentomics, and DNA methylation to detect early stage disease.

The PCR-based test is based on the US Centers for Disease Control and Prevention's CDC 2019-Novel Coronavirus Real-Time RT-PCR Diagnostic Panel.

Flagship Biosciences has launched a new clinical diagnostics immuno-oncology service called TissueInsight, which provides CLIA-reportable PD-L1 results along with data about a tumor's microenvironment to pathologists, oncologists, and immunologists to aid them in optimizing care for cancer patients. According to the company, users of the service follow their normal IHC slide staining process, then scan the slides and send the images to Flagship, which analyzes them with their proprietary image-analysis process. TissueInsight gives rapid, data-rich tissue interpretation and removes the inherent variability of subjective manual tissue scoring, the company said. Along with its CLIA-reportable results, TissueInsight tumor microenvironment data includes information on tumor infiltrating lymphocytes and macrophages, the company added.

The firm initially plans to apply the method, which measures the size of specific macrophages in blood, to predict lung cancer immunotherapy response.

With a three-pronged approach, a team led by Mount Sinai researchers examined the functional effects of noncoding de novo mutations on cardiac development.

A genomic analysis indicates chickens were domesticated from red jungle fowl more than 9,000 years ago, Science reports.

The New York Times reports on an effort to use gene editing to treat high cholesterol and triglyceride levels in monkeys.

According to Retraction Watch, Ohio State University's Carlo Croce is being sued by his former lawyers for payment.

In PLOS this week: computational approach to gauge penetrance of risk variants, evolution of seasonal influenza A strains, and more.

Cergentis of Utrecht, the Netherlands, this week announced a number of new appointments. Joris Schuurmans has become the firm's CEO, replacing Jan Dekker. Schuurmans joins Cergentis from Skyline Dx, where he led the melanoma program. Previously, he held senior executive positions at Biocartis and at MyCartis.

Further, Dirk Pollet and Maja Sanders have joined the company's supervisory board. Pollet is CEO of Enzyre and is the former CEO of Multiplicom, which was acquired by Agilent Technologies. Sanders holds supervisory roles at various organizations and has managerial experience in the private equity industry.

The company will use the funds to support its growth in the custom probiotics market, scale delivery of its products, and publish new studies.

Burning Rock also said it will continue to develop companion diagnostics-related products based on next-generation sequencing technology.

Last week, GenomeWeb's readers were most interested in Invitae's offer to acquire privately held ArcherDx in a deal worth $1.4 billion.